New mechanisms of viral persistence in primary human immunodeficiency virus (HIV) infection

Journal of Biological Regulators and Homeostatic Agents

Volumn 11, Issue 1-2, 1997, Pages 37-39

  Soudeyns, H ^a   Pantaleo, G ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Hôpital Beaumont 06 634   (Switzerland)

Author keywords

Acquired immunodeficiency syndrome; Acute infection; Cytotoxic T lymphocytes; Human immunodeficiency virus; Lymph nodes

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN;

CELLULAR IMMUNITY; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYMPH NODE; NONHUMAN; PERSISTENT VIRUS INFECTION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; MURINAE;

EID: 0030783736     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Butera ST, Roberts BD, Lam L, et al. Human immunodeficiency virus type 1 RNA expression by four chronically infected cell lines indicates multiple mechanisms of latency. J Virol 1994; 68: 2726-30.
2. Boshkov LK, J.L. Macen JL, McFadden G. Virus-induced loss of class I MHC antigens from the surface of cells infected with myxoma virus and malignant rabbit fibroma virus. J Immunol 1992; 148: 881-7.
3. Beersma MF, Bijlmakers MJ, Ploegh HL. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J Immunol 1993; 151: 4455-64.
4. Phillips RE, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991; 354: 453-9.
5. Niewiesk S, Daenke S, Parker CE, et al. Naturally occurring variants of human T-cell leukemia virus type I Tax protein impair its recognition by cytotoxic T lymphocytes and the transactivation function of Tax J Virol 1995; 69: 2649-53.
6. Klenerman P, Rowland-Jones S, McAdam S, et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 gag variants. Nature 1994; 369: 403-7.
7. Moskophidis D, Lechner F, Pircher H, et al. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993; 362: 758-61.
8. Zinkernagel RM. Immunology taught by viruses. Science 1996; 271: 173-8.
9. Labrecque N, McGrath H, Subramanyam M, et al. Human T cells respond to mouse mammary tumor virus-encoded superantigens: Vβ restriction and conserved evolutionary features. J Exp Med 1993; 177: 1735-43.
10. Soudeyns H, Rebai N, Pantaleo G, et al. The T cell receptor Vβ repertoire in HIV-1 infection and disease Sem Immunol 1993; 5: 175-85.
11. Rebai N, Pantaleo G, Demarest JF, et al Analysis of the T-cell receptor β-chain variable-region (Vβ) repertoire in monozygotic twins discordant for human immunodeficiency virus: evidence for perturbations of specific Vβ segments in CD4+ T cells of the virus-positive twin. Proc Natl Acad Sci USA 1994; 91: 1529-33.
12. Cossarizza A. T-cell repertoire and HIV infection: facts and perspectives. AIDS 1997; 11: 1075-1088.
13. Pantalco G, Demarest JF, Soudeyns H, et al. Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV Nature 1994; 370: 463-7.
14. Pantaleo G, Demarest JF, Schacker T, et al The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997; 94: 254-8.
15. Pantaleo G, Soudeyns H, Demarest JF, et al. Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci USA 1997; 94: 9848-53.
16. Pantaleo G, Graziosi C, Butini L, et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci USA 1991; 88: 9838-42.
17. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease Nature 1993; 362: 355-8.
18. Mondino A, Khoruts A, Jenkins M. The anatomy of T-cell activation and tolerance. Proc Natl Acad Sci USA 1996. 93; 2245-52.
19. Cohen OJ, Pantaleo G, Lam GK, et al. Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies. Springer Semin Immunopathol 1997; 18: 305-22.
20. MacDonald HR, Casanova JL, Maryanski JL, et al. Oligoclonal expansion of major histocompatibility complex class I-restricted cytolytic T lymphocytes during a primary immune response in vivo: direct monitoring by flow cytometry and polymerase chain reaction. J Exp Med 1993; 177: 1487-92.
21. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. New Engl J Med 1995; 333: 1534-9.
22. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. New Engl J Med 1995; 333: 408-13.
23. Perrin L, Rank A, Yerly S, et al. Combined therapy with zidovudine and L-697,661 in primary HIV infection. AIDS 1996; 10: 1233-7.
24. Cohen OJ, Pantaleo G, Holodniy M, et al. Decreased HIV-1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc. Natl. Acad. Sci. USA 1995; 92: 6017-21.
25. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997; 276: 960-4.
26. Pantaleo G. How immune-based interventions can change HIV therapy. Nature Medicine 1997; 3: 483.